Augmedix (NASDAQ:AUGX) Stock Rating Upgraded by Evercore ISI

Evercore ISI upgraded shares of Augmedix (NASDAQ:AUGX) from an in-line rating to an outperform rating in a report released on Tuesday morning, Benzinga reports. Evercore ISI currently has $5.00 price target on the stock, up from their prior price target of $4.50.

Several other equities research analysts also recently commented on AUGX. Maxim Group dropped their target price on Augmedix from $6.50 to $5.00 and set a buy rating on the stock in a report on Tuesday, March 19th. B. Riley began coverage on Augmedix in a report on Wednesday, April 3rd. They set a buy rating and a $5.50 target price on the stock.

Augmedix Stock Performance

Augmedix stock opened at $4.06 on Tuesday. The stock’s 50-day moving average is $4.17 and its 200-day moving average is $4.85. The company has a market cap of $197.88 million, a price-to-earnings ratio of -9.02 and a beta of -0.16. The company has a debt-to-equity ratio of 0.66, a current ratio of 2.41 and a quick ratio of 2.41. Augmedix has a 12 month low of $1.50 and a 12 month high of $6.25.

Insider Transactions at Augmedix

In related news, insider Ian Shakil sold 58,978 shares of the firm’s stock in a transaction that occurred on Monday, April 1st. The stock was sold at an average price of $3.91, for a total value of $230,603.98. Following the sale, the insider now owns 180,034 shares of the company’s stock, valued at approximately $703,932.94. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. In the last quarter, insiders sold 226,045 shares of company stock worth $906,249. 10.97% of the stock is currently owned by corporate insiders.

Institutional Trading of Augmedix

Several hedge funds have recently added to or reduced their stakes in AUGX. Russell Investments Group Ltd. raised its stake in Augmedix by 292.0% during the 4th quarter. Russell Investments Group Ltd. now owns 891,077 shares of the company’s stock valued at $5,213,000 after acquiring an additional 663,778 shares in the last quarter. Parkman Healthcare Partners LLC raised its stake in shares of Augmedix by 170.1% in the 4th quarter. Parkman Healthcare Partners LLC now owns 1,015,814 shares of the company’s stock worth $5,943,000 after buying an additional 639,732 shares in the last quarter. Essex Investment Management Co. LLC bought a new stake in shares of Augmedix in the 3rd quarter worth $2,237,000. Ameriprise Financial Inc. bought a new stake in shares of Augmedix in the 3rd quarter worth $1,250,000. Finally, Legato Capital Management LLC bought a new stake in shares of Augmedix in the 3rd quarter worth $840,000. Institutional investors own 87.11% of the company’s stock.

Augmedix Company Profile

Augmedix, Inc provides remote medical documentation solutions and live clinical support services in the United States. Its platform offers Augmedix Live that provides synchronous medical note documentation and point of care support; Augmedix Go Assist that offers asynchronous medical documentation based upon previously recorded visits; Augmedix Prep that provides patient demographics, past medical history, medication changes and other points from the patient's health record; and Augmedix Go, an autonomous, ambient AI mobile software application that offers fully automated medical documentation based upon recorded visits.